Application of CGP60474 in preparation of medicine for treating bladder cancer

Targeted inhibition of MITD1 by CGP60474, the problem of lack of effective targeted inhibitors in bladder cancer treatment was solved, significantly inhibiting the proliferation and migration of bladder cancer cells, providing a new treatment plan, significantly reducing the expression of MITD1 protein, and enhancing the bladder cancer cells inhibitory effect.

CN118924760APending Publication Date: 2024-11-12LANZHOU UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410811429.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-21
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The lack of sensitive markers has led to poor treatment of bladder cancer, and there is currently no effective MITD1-targeted inhibitor for bladder cancer treatment.

Method used

开发CGP60474作为一种高效的抗内毒素药物,通过靶向抑制MITD1来抑制膀胱癌细胞的增殖和迁移,提供新的治疗方案。

Benefits of technology

CGP60474 significantly inhibits the proliferation and migration of bladder cancer cells, provides new drug applications for treating bladder cancer, significantly reduces MITD1 protein expression, and enhances the inhibitory effect on bladder cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to application of CGP60474 in preparation of a medicine for treating bladder cancer, provides novel pharmaceutical activity, namely bladder cancer resisting activity, of the CGP60474, is used for preparing the medicine for treating the bladder cancer, and belongs to the field of medicine. According to the application disclosed by the invention, research finds that the CGP60474 has a good in-vitro anti-tumor effect on bladder cancer cells, and the CGP60474 inhibits the proliferation of the bladder cancer cells and inhibits the migration of the bladder cancer cells by reducing the expression of MITD1 protein. The CGP60474 provides a new treatment scheme for bladder cancer, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention provides a new drug activity of CGP60474, namely, reducing MITD1 expression and inhibiting bladder cancer cell proliferation, so as to be used for preparing a drug for treating bladder cancer, and belongs to the field of medicine. Background Art

[0002] The lack of sensitive biomarkers is the primary reason for the failure of bladder cancer treatment.

[0003] MITD1 (microtubule-interacting and trafficking domain containing 1) is a key protein involved in the abscission process of cell mitosis. It binds to ESCRT-III to ensure that cells complete effective abscission. Abnormal MITD1 causes midbody instability and abscission failure, which can lead to genetic damage and tumorigenesis. MITD1 can be used as a new target for the treatment of bladder cancer. The development of targeted MITD1 inhibitors is crucial for the treatment of bladder cancer. At present, the application of targeted inhibitors of MITD1 in bladder cancer has not been reported.

[0004] CGP60474 is a highly effective anti-endotoxin drug that inhibits cyclin-dependent kinase (CDK). It has not yet been used in the treatment of bladder cancer and is expected to be used as a targeted inhibitor of MITD1. Summary of the invention

[0005] The present invention aims to provide the use of CGP60474 in the preparation of a drug for treating bladder cancer. The present invention finds that CGP60474 has a good anti-tumor effect on bladder cancer cells, has a significant inhibitory effect on the proliferation of bladder cancer cells, and can also inhibit the migration of bladder cancer cells. This indicates that CGP60474 provides a new treatment plan for the treatment of bladder cancer.

[0006] To achieve the above object, the present invention adopts the following technical solution: The present invention provides use of CGP60474 in preparing a medicine for treating bladder cancer.

[0007] This use is achieved through one or more of the following: (A) CGP60474 inhibits the proliferation of bladder cancer cells by targeting MITD1. (B) CGP60474 inhibits the migration of bladder cancer cells.

[0008] The bladder cancer cells are preferably J82 cells or UMUC-3 cells.

[0009] The drug is prepared into a pharmaceutically acceptable dosage form by adding CGP60474 as an active ingredient to a pharmaceutically acceptable carrier and / or excipient, and the dosage form is any one of tablets, sprays, granules, capsules, oral liquids, injections, and suspensions.

[0010] The present invention first discovered that CGP60474 can inhibit the proliferation of human bladder tumor cells. It was further discovered that CGP60474 can target and reduce the expression of MITD1 protein, and has a significant inhibitory effect on the proliferation of bladder cancer cells, providing a new treatment plan for the treatment of bladder cancer.

[0011] Beneficial effects of the present invention: The present invention provides the use of CGP60474 in the preparation of a drug for treating bladder cancer. CGP60474 inhibits the proliferation of bladder cancer cells by reducing the expression of MITD1 protein, and can inhibit the migration of bladder cancer cells. The present invention clarifies through research that CGP60474 has a good in vitro anti-tumor effect on bladder cancer cells J82 and UMUC-3, has a significant inhibitory effect on the proliferation of bladder cancer cells J82 and UMUC-3, and the inhibitory effect increases with the increase of drug concentration; it can also inhibit the migration of bladder cancer cells J82 and UMUC-3. It provides a new way and means for preparing new drugs for treating bladder cancer, and provides new ideas for treating bladder cancer in medical applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 is the structural formula of CGP60474; Figure 2 Schematic diagram of MITD1 receptor binding site; Figure 3 This is a diagram of the interaction pattern between CGP60474 and MITD1; Figure 4 CGP60474 inhibits the proliferation of human bladder cancer cells in vitro; Figure 5 CGP60474 inhibits the colony formation of bladder cancer cells UMUC-3 and J82; Figure 6 CGP60474 inhibits the migration of bladder cancer cells UMUC-3; Figure 7 CGP60474 inhibited MITD1 expression in bladder cancer cells UMUC-3 and J82 in a concentration-dependent manner; Figure 8 For cell thermal shift experiment. DETAILED DESCRIPTION

[0013] The present invention has no particular limitation on the specific source of CGP60474, and it can be synthesized by conventional chemical synthesis methods in the art. CGP60474 has good preparability and stability, and can also be purchased from commercial sources.

[0014] The structural formula of CGP60474 of the present invention is as follows Figure 1 In the present invention, the bladder cancer cells are preferably J82 cells and UMUC-3 cells. In the present invention, when CGP60474 is used to prepare a drug for treating bladder cancer, it can be used as the only active ingredient of the drug, or it can be combined with other active ingredients that have the effect of treating bladder cancer.

[0015] The present invention does not specifically limit the types of pharmaceutically acceptable excipients, and any conventional pharmaceutically acceptable excipients in the art may be used. In the present invention, the dosage form of the drug includes injections, tablets, capsules or granules, and the injections include intravenous injections and subcutaneous injections. The drug of the present invention can be applied to clinical practice through a variety of administration routes such as oral, intravenous, and subcutaneous injections, and has greater flexibility and convenience. Moreover, CGP60474 is used as the active ingredient of the drug, which can produce lower drug resistance to bladder cancer cells, thereby reducing the occurrence of treatment failure and recurrence.

[0016] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0017] In the following embodiments, unless otherwise specified, all of them are conventional methods.

[0018] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0019] Example 1. CGP60474 targets and binds to MITD1.

[0020] (1) Obtaining the structural model of MITD1 and analyzing the small molecule binding site. MITD1 is 249 amino acids in length, and currently has three crystal structures resolved, of which 2YMB and 4A5X are complex structures of MITD1 and CHMP1A proteins, and 4A5Z is a homodimer of MITD1. MITD1 has a microtubule interaction and transport (MIT) domain at the N-terminus and a unique and unexpected phospholipase-like (PLD) domain at the C-terminus of the membrane binding site. Structural comparison of 2YMB, 4A5Z and Alphafold predicted structures showed an RMSD of 0.68Å. The results showed that the 3D structures of 2YMB, 4A5Z and Alphafold predicted structures were consistent in the 90-243 sequence. At the same time, the resolution of 4A5Z was better, so the 4A5Z crystal structure was selected for virtual screening. Mutation of MITD1 dimer-PPI interface residues Y132, F221, and Y225 to A (MUT YFY) abolished dimerization. The protein binding sites were predicted by MOE, and the results showed that there was 1 good site (PLB>1) (SER102 TYR103 GLU104 SER105 PHE107 ARG108 LEU111 ASN112 HIS129 TYR1 32 ASN133 ARG136 GLU139 MET140 LYS143 ARG144 PRO145 CYS146 ARG209 LEU211 ASP212 TYR213 PHE214 LYS215 LYS216 PRO217 SER219 ARG220 TYR225 CYS226 ASP227 PHE228 ASP229 ARG231 HIS234) 2: (SER102 TYR103 GLU104 SER105 ARG108 HIS129 TYR132 ASN133 ARG136GLU139 MET140 LYS143 ARG144 PRO145 LEU211 ASP212 TYR213 PHE214 LYS215 LYS216PRO217 TYR225 CYS226ASP227 PHE228 AS P229 ARG231), among which Site1 contains amino acids Y132 and Y225, and Site1 was selected for virtual screening.

[0021] (2) Processing of the target protein structure. The structure of the MITD1 crystal was downloaded from the official website of the Protein Data Bank (https: / / www.rcsb.org / structure / 4A5Z). The Protein Preparation Wizard module [1] in the Schrödinger software was used to perform bond optimization, hydrogenation, disulfide bond assignment, hydrogen bond assignment, and energy minimization on the protein.

[0022] (3) Preparation of small molecule compound library. The T001 compound library with good diversity (provided by TOPSCIENCE, https: / / www.tsbiochem.com / ) was selected. The compounds in the compound library were processed using the LigPrep module in the Schrödinger software, with the forcefield set to OPLS4. The Epik method was used to protonate and desalt at pH 7.0±2.0 to generate tautomers while maintaining the original atomic chirality. In order to ensure the global conformation of small molecules during virtual screening, conformation generation was performed on small molecules, with a maximum of 32 conformations generated for each small molecule. The prepared compounds were saved for subsequent virtual screening.

[0023] (4) Molecular docking. The prepared receptor and ligand files were imported, and a step-wise strategy (i.e., HTVS [high-throughput virtual screening mode] → SP [standard precision mode] → XP [extra precision mode]) was used to gradually improve the accuracy of the screening mode. The key parameters of each step were the default values. The small molecule flexible docking method was used. After docking, energy optimization was performed, and small molecules with a docking score of 80% were retained for the next round of screening. 6252 compounds were obtained. 627 compounds with a docking score less than -7 kcal / mol were selected for further analysis of their binding mode. It was found that 612 compounds could form hydrogen bonds and other interactions with MITD1. 612 compounds were further predicted. The pharmacokinetic properties of compounds were analyzed, and 246 compounds were found to have good ADME / T properties. The 246 compounds were clustered under the similarity coefficient = 0.7 parameter to analyze their diversity. Through cluster analysis, 127 types of compounds were obtained, and 1-2 compounds with the best docking scores were selected for each type of compound, totaling 177 compounds. After eliminating the compounds without stock, 169 compounds were obtained. During the screening process, some important data are saved in the attachments. These files contain information such as 3D pharmacodynamic conformation information of small molecules, compound ID, affinity score, drugability score, drugability attribute value, and physicochemical properties of compounds.

[0024] Figure 2 Schematic diagram of the MITD1 receptor binding site, showing the CGP6047 and MITD1 binding site.

[0025] Figure 3 The diagram of the interaction pattern between CGP60474 and MITD1 (green is the interaction area and the amino acids that interact are magnified, magenta is compound CGP60474, and the red dotted line represents hydrogen bonds). Through comprehensive analysis, CGP60474 was selected. The affinity value of compound CGP60474 binding to MITD1 protein is -8.46 kcal / mol. The main binding mode is that -OH and -NH on compound CGP60474 form hydrogen bond interactions with Y103 and E139 of MITD1 protein A chain respectively; N on pyrimidine on compound CGP60474 and amino acids adjacent to pyrimidine can form hydrogen bond interactions with K143 and E104 of MITD1 protein B chain respectively, thereby increasing the stability of compound binding to protein.

[0026] Example 2: CGP60474 inhibits proliferation of human bladder cancer in vitro (1) Seed plate: Digest bladder cancer cells in the logarithmic growth phase with trypsin, resuspend in complete medium to make a cell suspension, count, and adjust the cell density to 1×10 5 / ml, add 100 μL of tumor cell suspension to each well of the 96-well plate and culture in an incubator; (2) Intervention: After 8-12 hours of culture, the cells were observed to be well attached to the wall. The culture medium of each well was aspirated, and different concentrations of CGP60474 and normal culture medium of the control group were added to the corresponding wells, and the culture was continued for 24 h, 48 h, and 72 h. (3) Measure absorbance: Add 10 μL of CCK-8 solution to each well and incubate for 2 hours. Measure the absorbance at 450 nm using an ELISA reader.

[0027] Figure 4 The results show that CGP60474 inhibits the proliferation of human bladder cancer cells in vitro. AC. CCK8 experiments confirmed that CGP60474 inhibited the proliferation of human bladder cancer cells UMUC-3 and UMUC-3 MITD1 OE in a concentration (0μM, 0.008μM, 0.04μM and 0.2μM)-dependent and time (24h, 48h and 72h)-dependent manner, and had no significant inhibition on the proliferation of UMUC-3sh MITD1 cells. DF. CCK8 experiments confirmed that CGP60474 inhibited the proliferation of human bladder cancer cells J82 and J82 MITD1 OE in a concentration (0μM, 0.008μM, 0.04μM and 0.2μM)-dependent and time (24h, 48h and 72h)-dependent manner, and had no significant inhibition on the proliferation of J82 shMITD1 cells.

[0028] Example 3: CGP60474 inhibits bladder cancer cell clone formation (1) Plating: Digest the bladder cancer cell lines in the logarithmic growth phase with trypsin, resuspend in complete medium to make a cell suspension, count the cells, and plate 500 cells of the bladder cancer cell lines UMUC-3, UMUC-3, UMUC-3 sh MITD1, UMUC-3MITD1 OE, J82, J82sh MITD1, and J82 MITD1 OE in each well of a six-well plate.

[0029] (2) Intervention: The next day, all cells were observed to be attached to the wall, the original culture medium was discarded, and the cells were incubated with culture medium containing different concentrations of CGP60474. The control group continued to culture with normal culture medium. The medium was changed every 3 days and the cell status was observed. The clone size was observed under a microscope and the culture was continued for 2 weeks. (3) Fixation: Aspirate the supernatant, remove the upper chamber, wash the cells once with PBS, add 1 mL of 4% paraformaldehyde to each well, fix the cells at room temperature for 40 min, and wash the cells once with PBS.

[0030] (4) Staining: Add 1 mL of clean, impurity-free crystal violet stain to each well and stain the cells for 30 min. Wash the cells several times, dry them, take pictures, and count the colonies.

[0031] Figure 5 CGP60474 inhibits the clone formation of bladder cancer cells UMUC-3 and J82; CGP60474 inhibits the clone formation of bladder cancer cells, but after knocking down MITD1, CGP60474 has no obvious inhibition on the clone formation of UMUC-3 sh MITD1 and J82 sh MITD1 cells.

[0032] Example 4: CGP60474 inhibits the migration of bladder cancer cells (1) Plating: Digest the bladder cancer cell line in the logarithmic growth phase with trypsin, resuspend in complete medium to make a cell suspension, count, and plate 8×10 cells per well in each of the six-well plates. 5 Bladder cancer cells, the cell density can reach more than 90% the next day; (2) Scratching: The next day, observe that all cells are attached to the wall, discard the original culture medium, use a 200μL pipette tip to vertically aim at the lower chamber of the 6-well plate and gently scratch the cell monolayer to form a scratch. Use PBS to gently rinse 2-3 times to wash away the cells damaged during the scratching process, add serum-free culture medium and take pictures under a microscope; (3) Intervention: Cells were incubated with serum-free medium containing different concentrations of CGP60474 in a 37°C, 5% CO2 incubator for 24 and 48 h, and then photographed again using a microscope; (4) Analysis: ImageJ software was used to analyze the scratch healing area.

[0033] Figure 6CGP60474 inhibits the migration of bladder cancer cells UMUC-3. CGP60474 inhibits the migration ability of bladder cancer cells UMUC-3.

[0034] Example 5: CGP60474 inhibits the expression of MITD1 protein (1) Plating: Digest the bladder cancer cell line in the logarithmic growth phase with trypsin, resuspend in complete medium to make a cell suspension, count, and plate 1×10 cells per well of a six-well plate. 5 Bladder cancer cells UMUC-3 and J82.

[0035] (2) Intervention: The next day, all cells were observed to be adherent to the wall. The original culture medium was discarded and the cells were incubated with culture medium containing different concentrations of CGP60474 for 24 hours.

[0036] (3) Cell protein extraction: ① When the adherent cells in the 6-well plate are fused to about 90%, discard the old culture medium and wash the adherent cells twice with 4°C pre-cooled PBS, and absorb as much PBS buffer as possible; ② Add 150 μL of pre-cooled RIPA lysis mixture (containing PMSF and phosphatase inhibitors) to each well, place the 6-well plate horizontally on ice for 20 minutes, collect the lysate into a 1.5 mL EP tube with a clean pre-cooled cell scraper, and ultrasonically disrupt the cells twice at 200w, 5 seconds each time; ③ Centrifuge at 4°C, 12,000 rpm for 15 min, and transfer the supernatant into a new pre-cooled EP tube for protein concentration determination.

[0037] (4) Determination of target protein concentration by BCA method: ① Take 20 μL of ready-to-use BSA standard and add it to a 96-well plate; ② Add 1 μL of the protein sample to be tested to the sample well of the 96-well plate, set up 2 replicate wells, and then add 19 μL of PBS buffer to make the volume of each well 20 μL; ③ According to the calculated amount of color working solution required, prepare the color working solution by mixing reagent A and reagent B at a volume ratio of 50:1, mix thoroughly, add 200 μL of color working solution to each well, cover the 96-well plate, incubate at 37°C for 30 min, and cool to room temperature; ④ Use an ELISA reader to measure the A562 of each sample and BSA standard, draw a standard curve using Excel, calculate the protein concentration of the sample, and adjust the protein concentration of each sample to a similar level using PBS buffer; ⑤ Add 1 / 5 volume of 5× loading buffer to the protein sample, denature in a metal bath at 100℃ for 5 minutes, aliquot, and store at -80℃.

[0038] (5) Protein gel electrophoresis: ① Gel preparation: A. Rinse with distilled water and blow dry the glass plate with a hair dryer, and fix the glass plate vertically on a special cardboard for gel preparation; B. Take a 1.0mm gel as an example, take 2.5mL of the lower gel solution and lower gel buffer in the one-step PAGE gel rapid preparation kit, and mix them; take 750μL of the upper gel solution and the colored upper gel buffer, and mix them; C. Add 60μL of the improved coagulant to the lower gel mixed solution, mix gently, and inject the mixed solution into the gel glass plate, so that the distance between the liquid surface and the upper edge of the short glass plate is 0.5 cm longer than the comb teeth; D. Add 15μL of the improved coagulant to the upper gel mixed solution, mix gently, and inject the mixed solution into the gel glass plate without waiting for the lower gel to solidify, and insert the comb teeth; after the gel solidifies, remove the comb teeth and use it for electrophoresis; ② Sample electrophoresis: add 10μL, 50μg of protein sample to each well, turn on the power and select 80V for electrophoresis. After about 20 minutes, you can see that the blue sample is arranged in a straight line at the bottom of the concentrated gel. At this time, adjust the electrophoresis voltage to 120V. Continue electrophoresis for about 1 hour; (6) Transfer: ① Gel cutting: Cut the gel according to the molecular weight of the target protein and refer to the marker, and cut the PVDF membrane of corresponding size according to the molecular weight of the gel and the target protein; ② Soak the PVDF membrane in methanol for 15 seconds to activate it, then soak it in ultrapure water for 2 minutes, and finally balance it in the electroporation solution for 5 minutes; ③ Place the filter paper, glue, PVDF membrane and filter paper in the black plate at the bottom in order. After all bubbles are removed, insert the membrane transfer tank. If the target protein has a molecular weight less than 70KD, transfer it at a constant current of 300mA for 20 minutes.

[0039] (7) Blocking: Use tweezers to hold the PVDF membrane and place it in a blocking incubation box containing 5% skimmed milk powder for blocking. Slowly shake the membrane on a decolorizing shaker at room temperature for 1 hour. (8) Incubation with primary antibody: After blocking, wash the PVDF membrane three times with TBST for 5 minutes each time, then place the strips in the corresponding primary antibody and incubate overnight at 4°C; (9) Incubation with secondary antibody: The next day, wash the membrane three times with TBST, with washing time of 5 min and 10 min respectively. Then incubate with the secondary antibody corresponding to the primary antibody species and incubate on a shaker at room temperature for 1 hour; (10) Exposure: After the secondary antibody incubation is completed, the membrane is washed three times with TBST, with washing times of 5 min, 10 min, and 10 min respectively, and then the Odyssey CLX near-infrared dual-color fluorescence imaging system is turned on for exposure.

[0040] Figure 7 CGP60474 inhibited the expression of MITD1 in bladder cancer cells UMUC-3 and J82 in a concentration-dependent manner. The experimental results showed that CGP60474 (0μM, 0.0016μM, 0.008μM, 0.04μM 0.2μM and 1μM) inhibited the expression of MITD1 in bladder cancer cells UMUC-3 and J82 in a concentration-dependent manner.

[0041] Example 6: CGP60474 binds to MITD1 in UMUC-3 bladder cancer cells (1) Cell preparation and treatment. UMUC-3 cells were routinely cultured in 10 10 cm cell culture dishes. After the cells were fully grown, they were randomly divided into a control group and an experimental group with 5 dishes each. CGP60474 was added to the culture medium of the experimental group at a final concentration of 0.04 uM, and the same volume of PBS was added to the control group as a control. The culture was continued for 4 h. Then, 10 ml of the cell suspension was collected for digestion (four groups in total, four 15 ml EP tubes) and centrifuged at 300 g for 3 min at room temperature, the supernatant was discarded, and the cells were resuspended in 2 ml PBS and centrifuged at 300 g for 3 min at room temperature, and the supernatant was discarded; each group (1.1 ml) was distributed to 10 0.2 ml EP tubes (a total of 40 0.2 ml EP tubes, each 105 ul), and each tube (tube cap, tube body) was labeled (40, 43, 46, 49, 52, 55, 58, 61, 64, 67 °C).

[0042] (2) Heat treatment of cell suspension for 10 min. In the PCR instrument, heat the first six tubes (40-55 ℃) of each group at the specified temperature for 3 min (when the temperature of each well of the PCR instrument rises to the specified temperature, place the EP tube), leave it at room temperature for 3 min, quickly freeze the first six tubes (40-55 ℃) of heat-treated cell suspension in liquid nitrogen (3 min), and place it in a -80 ℃ refrigerator. Then heat the last four tubes (58-67 ℃) at the specified temperature for 3 min and leave it at room temperature for 3 min.

[0043] (3) Quickly freeze the heat-treated cell suspension in liquid nitrogen. Quickly freeze the remaining four tubes (58-67 ℃) of heat-treated cell suspension in liquid nitrogen (3 min), then thaw all EP tubes at 25 ℃, then vortex, repeat liquid nitrogen for 3 min, thaw at 25 ℃, for a total of two freeze-thaw cycles. After each thawing, briefly vortex the test tube. Then put the EP tube on ice again. Cut off the front cap of the 0.2ml EP tube and put it in a 1.5ml EP tube, then centrifuge at 4 ℃ and 12,000 rpm for 15 min to precipitate the cell fragments and precipitated proteins, and put it on ice after centrifugation. Transfer the supernatant to a new EP tube (re-label 40 tubes) (do not touch the precipitate, calculate the amount of protein in each tube, add non-denaturing reducing loading buffer), vortex briefly, centrifuge, and heat denature at 70 ℃ for 10 min.

[0044] (4) Western Blot was used to detect the expression of MITD1 in the remaining proteins.

[0045] Figure 8 This is a cell thermal shift experiment, which shows that CGP60474 can stably bind to MITD1 in bladder cancer cells.

[0046] The above experiments and graphs show that compared with the negative control group, CGP60474 has a good in vitro anti-tumor effect on bladder cancer cells J82 and UMUC-3.

[0047] The above is only the preferred embodiment of the present application, which does not limit the protection scope of the present application. For those skilled in the art, the present application may have various changes and modifications. Within the spirit and principle of the present application, the changes, modifications, replacements, integrations and parameter changes of these embodiments by conventional substitutions or capable of achieving the same functions without departing from the principles and spirit of the present application shall fall within the protection scope of the present application.

Claims

1. Application of CGP60474 in the preparation of drugs for treating bladder cancer.

2. The use of CGP60474 according to claim 1 in the preparation of a drug for treating bladder cancer, characterized in that: CGP60474 inhibits the proliferation of bladder cancer cells by reducing the expression of MITD1 protein.

3. The use of CGP60474 according to claim 1 in the preparation of a drug for treating bladder cancer, characterized in that: CGP60474 inhibits the migration of bladder cancer cells.

4. The use of ESI-09 according to claim 1 in the preparation of a drug for treating bladder cancer, characterized in that: The drug is prepared into a pharmaceutically acceptable dosage form by adding CGP60474 as an active ingredient to a pharmaceutically acceptable carrier and / or excipient.

5. The use of ESI-09 according to claim 4 in the preparation of a drug for treating bladder cancer, characterized in that: The dosage form is any one of tablets, sprays, granules, capsules, oral liquids, injections, and suspensions.

Citation Information

Patent Citations

  • Selenium-containing compound and medical application thereof

    CN113527329A

  • Application of compound CGP60474 in preparation of medicine for treating and preventing diseases caused by herpes virus type I

    CN117618434A

  • Diagnosis and regulation of epidermal differentiation and cancer cell activity

    US20210023083A1

  • Pharmaceutical composition for preventing or treating colorectal cancer comprising ednra inhibitor as active ingredient

    WO2023163497A1